Berlin, Germany – Elevance Health, one of the nation’s largest health insurers, is facing significant disruption as the Centers for Medicare & Medicaid Services (CMS) intends to suspend enrollment in its Medicare Advantage prescription drug plans, beginning March 31st. The move, announced Monday, stems from a seven-year failure by Elevance to provide required data to federal regulators, raising concerns about the quality of care and administrative practices within the company’s Medicare Advantage program. The news sent Elevance’s stock price tumbling more than 8% during trading hours, signaling investor anxiety about the potential financial repercussions.
The suspension will not immediately impact the approximately 1.9 million individuals currently enrolled in Elevance Medicare Advantage plans for 2024. However, it prevents the company from attracting new beneficiaries during a critical enrollment period, potentially hindering future growth and market share. CMS indicated that Elevance could avert the suspension if it takes corrective action this month to address the data submission issues. This situation highlights the increasing scrutiny of Medicare Advantage plans, which have grown rapidly in popularity but have likewise faced criticism regarding their complexity and potential for denying necessary care.
This action by CMS is particularly noteworthy given the relative rarity of such severe sanctions against major Medicare Advantage providers. The agency’s decision underscores the importance of accurate and timely data reporting for ensuring accountability and transparency within the Medicare system. The implications extend beyond Elevance, potentially prompting other insurers to review their compliance procedures and data submission practices.
Elevance’s Legal Battles and CMS Concerns
The CMS suspension follows a recent legal defeat for Elevance. In October 2025, the company sued CMS over its Medicare Advantage star ratings, arguing that the agency’s methodology was flawed. However, a federal judge, appointed by former President Trump, dismissed Elevance’s claims, stating the company had “ignored basic math” in its assessment of the ratings. Bob Herman of STAT News reported on the ruling, emphasizing the judge’s critical assessment of Elevance’s arguments. This legal setback further compounds the challenges facing the company as it navigates the CMS suspension.
The core issue driving the CMS sanction revolves around Elevance’s failure to submit required information over a sustained period. Although the specific data in question has not been publicly detailed, the agency’s statement suggests it relates to key performance metrics and compliance reporting essential for overseeing the quality and efficiency of Medicare Advantage plans. The seven-year timeframe of non-compliance indicates a systemic issue within Elevance’s data management processes, rather than an isolated incident.
Medicare Advantage: Growth and Scrutiny
Medicare Advantage plans, offered by private insurers like Elevance, have become increasingly popular with Medicare beneficiaries. These plans often offer additional benefits, such as vision, dental, and hearing coverage, that are not typically included in traditional Medicare. As of 2025, over 50% of Medicare beneficiaries were enrolled in Medicare Advantage plans, according to the Kaiser Family Foundation. This growth has been fueled by aggressive marketing and the appeal of supplemental benefits.
However, the rapid expansion of Medicare Advantage has also drawn scrutiny from policymakers and consumer advocates. Concerns have been raised about potential issues such as prior authorization requirements, limitations on provider networks, and the accuracy of risk adjustment data used to determine payments to insurers. The CMS suspension of Elevance’s enrollment highlights the agency’s commitment to holding insurers accountable for ensuring quality care and compliance with regulations.
What is Risk Adjustment?
Risk adjustment is a crucial component of the Medicare Advantage program. It’s a system designed to compensate insurers for enrolling beneficiaries with complex health conditions. Insurers submit data on their enrollees’ diagnoses, and CMS uses this information to adjust payments based on the expected healthcare costs of the population. Accurate data submission is paramount for ensuring fair and equitable payments, and for preventing insurers from cherry-picking healthier beneficiaries. The issues with Elevance’s data submission likely relate to this risk adjustment process.
Impact on Beneficiaries and the Market
While current Elevance Medicare Advantage enrollees will not be immediately affected by the suspension, the inability to enroll new members could have long-term consequences for the company and its beneficiaries. A reduced membership base could lead to higher premiums for existing members, as the cost of providing care is spread across a smaller pool of individuals.
The suspension also creates uncertainty for beneficiaries who were considering enrolling in an Elevance Medicare Advantage plan. These individuals will need to explore alternative options, potentially leading to increased competition among other insurers offering Medicare Advantage plans in the affected areas. The situation underscores the importance of beneficiaries carefully researching and comparing plans before making a decision.
The financial implications for Elevance are substantial. The suspension of enrollment could significantly impact the company’s revenue and growth projections. Analysts estimate that the company could lose millions of dollars in potential revenue if the suspension remains in effect through the annual enrollment period in October. The company’s stock performance on Monday, with a decline of over 8%, reflects investor concerns about the financial impact of the CMS action.
Looking Ahead: Corrective Action and Potential Outcomes
Elevance has indicated its intention to work with CMS to address the data submission issues and resolve the suspension. The company’s ability to demonstrate significant progress in the coming weeks will be critical in determining whether the suspension is lifted before the start of the annual enrollment period. CMS has stated that it will consider lifting the suspension if Elevance takes “certain steps” to address the issues, but the specific requirements have not been publicly disclosed.
The situation is being closely watched by other Medicare Advantage insurers, who may be prompted to review their own compliance procedures and data reporting practices. The CMS action sends a clear message that the agency is serious about enforcing regulations and ensuring accountability within the Medicare Advantage program.
The next key development will be CMS’s assessment of Elevance’s corrective actions. A decision is expected before the annual enrollment period begins in October 2026. Beneficiaries considering Medicare Advantage plans are encouraged to visit the official Medicare website for up-to-date information and resources.
This is a developing story, and we will continue to provide updates as more information becomes available. Share your thoughts and experiences in the comments below.